Replies to post #85 on BioXcel Therapeutics Inc (BTAI)

[realfast95]

BioXcel forms oncology subsidiary to free up neuroscience focus

https://www.thepharmaletter.com/article/bioxcel-forms-oncology-subsidiary-to-free-up-neuroscience-focus

At the same time as announcing strategic financing agreements worth $260 million, USA-based BioXcel Therapeutics (Nasdaq: BTAI) has revealed the formation of wholly-owned subsidiary OnkosXcel Therapeutics to develop transformative medicines in oncology.

OnkosXcel is focused on the sustained expansion and optimization of the oncology franchise, while providing maximum strategic and financial flexibility, and will progress the development of BXCL701, an…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.